SAN Sanofi

Sanofi :  INFORMATION ON THE FINAL TERMS OF DEPARTURE OF OLIVIER BRANDICOURT, FORMER CHIEF EXECUTIVE OFFICER

Sanofi :  INFORMATION ON THE FINAL TERMS OF DEPARTURE OF OLIVIER BRANDICOURT, FORMER CHIEF EXECUTIVE OFFICER

 PRESS RELEASE

 INFORMATION ON THE FINAL TERMS OF DEPARTURE OF OLIVIER BRANDICOURT, FORMER CHIEF EXECUTIVE OFFICER

Paris, on April 28, 2020

Given the shareholders’ vote on Olivier Brandicourt’s compensation for fiscal year 2019 during the General Meeting held today and following the Board of Directors’ meeting held after the Shareholders’ Meeting, Sanofi discloses the final terms of departure of Olivier Brandicourt, former Chief Executive Officer, in office until August 31, 2019.

Fixed compensation

The fixed compensation of Olivier Brandicourt with respect to financial year 2019 amounted to 800,000 euros. It was apportioned on a time basis from January 1, 2019 through August 31, 2019, the date of his departure from office as Chief Executive Officer.

Variable compensation

Given the rejection of the 19th resolution and pursuant to the provisions of the second paragraph of Article L. 225-100 III of the French Commercial Code, the variable compensation of Olivier Brandicourt for the period January 1, 2019 to August 31, 2019, set at 1,161,000 euros (amount apportioned on a time basis) after review of the level of attainment of the performance conditions by the Board of Directors in its March 4, 2020 meeting, will not be paid.

Top-up defined benefit pension rights

As a reminder, the vesting of the contingent rights under the top-up benefit pension plan to which Olivier Brandicourt was entitled on retirement was subject to a performance condition related to the attainment level of the variable portion of the Chief Executive Officer’s compensation.

Given the rejection of the 19th resolution, the benefits that Olivier Brandicourt will receive under the top-up pension scheme will integrate the rights acquired until December 31, 2018. Consequently, the final amount of the top-up pension is 501,241 euros per year, or 20.6150% of his reference compensation (capped at 60 times the annual French social security ceiling, representing a cap of €2,431,440 in 2019).

As a reminder, in accordance with the Compensation policy for the Chief Executive Officer, payment of this top-up pension is separate from any other termination benefit or non-compete indemnity.

Ongoing equity-based compensation plans

Pursuant to the compensation policy for the Chief Executive Officer which provides for a continuation of rights in the event of retirement, the Board of Directors had confirmed the retention of the rights of Olivier Brandicourt under stock option plans and performance share plans that have not yet vested.

As a reminder, the options and performance shares initially granted remain bound by the terms of the plans, including performance and non-competition conditions.  

***

 

Attachment

EN
28/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Press Release: Sanofi reaches agreement with the US government to lowe...

Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation Agreement delivers on President Trump’s four requests, establishing a framework for lower prices for patients in the US and a tariff-free accord for SanofiShowcases commitment to US manufacturing, innovation, and economic growth Paris, December 19, 2025. Sanofi today announced an agreement with President Donald J. Trump's Administration to help ensure American patients ha...

 PRESS RELEASE

Communiqué de presse : Sanofi conclut un accord avec le gouvernement a...

Communiqué de presse : Sanofi conclut un accord avec le gouvernement américain pour réduire le coût des médicaments et renforcer l’innovation Sanofi conclut un accord avec le gouvernement américain pour réduire le coût des médicaments et renforcer l’innovation L’accord répond aux quatre demandes du président Trump, établit un cadre pour que les patients américains bénéficient de prix plus bas et exempte Sanofi de droits de douaneL’accord illustre l’engagement de Sanofi à soutenir la production, l’innovation et la croissance économique aux États-Unis Paris, le 19 décembre 2025. Sanofi a an...

 PRESS RELEASE

Press release: Availability of the Q4 2025 Aide memoire

Press release: Availability of the Q4 2025 Aide memoire Availability of the Q4 2025 Aide memoire Paris, France – December 17, 2025. Sanofi announced today that its Q4 2025 Aide memoire is available on the "Investors" page of the company's website: As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items, as well as the foreign currency impact and share count. Sanofi's fourth quarter & full year 2025 results will be published on January 29, 2026. About Sanof...

 PRESS RELEASE

Communiqué de presse : Mise en ligne du document «Q4 2025 Aide mémoire...

Communiqué de presse : Mise en ligne du document «Q4 2025 Aide mémoire » Mise en ligne du document «Q4 2025 Aide mémoire » Paris, France, le 17 décembre 2025. Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q4 2025 Aide mémoire ». Comme chaque trimestre, ce document vise à assister la communauté financière dans la modélisation des résultats trimestriels de la société. Ce document contient un rappel de divers éléments non récurrents, l’effet des variations monétaires et le nombre d’actions. Les résultats du quatrième tri...

 PRESS RELEASE

Press Release: Sanofi’s efdoralprin alfa earns orphan designation in t...

Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema Additional orphan designation reinforces Sanofi’s commitment to developing treatments for rare diseasesEfdoralprin alfa, an investigational restorative recombinant therapy, recently met all primary and key secondary endpoints in phase 2 head-to-head study versus a plasma-derived standard of care Paris, December 17, 2025. The European Medicines Agency...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch